S. Aebi

发表

M. Castiglione, S. Aebi, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

A randomized crossover trial assessing patient preference for two different types of portable infusion-pump devices.

M. Fey, S. Aebi, D. Zahnd, 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

Characterization of male breast cancer: results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program

Melissa P. Murray, O. Bogler, C. Hudis, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Maastricht Delphi consensus on event definitions for classification of recurrence in breast cancer research.

M. Piccart, A. Giuliano, C. Hudis, 2014, Journal of the National Cancer Institute.

Genomic Aberrations and Late Recurrence in Postmenopausal Women with Hormone Receptor–positive Early Breast Cancer: Results from the SOLE Trial

P. Neven, A. Goldhirsch, G. Viale, 2020, Clinical Cancer Research.

Newly and relapsed epithelial ovarian carcinoma: ESMO clinical recommendations for diagnosis, treatment and follow-up.

M. Castiglione, S. Aebi, M. Castiglione, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

Epithelial ovarian carcinoma: ESMO clinical recommendations for diagnosis, treatment and follow-up.

M. Castiglione, S. Aebi, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

A nurse is a nurse? A systematic review of the effectiveness of specialised nursing in breast cancer.

S. Aebi, M. Eicher, S. Marquard, 2006, European journal of cancer.

Capecitabine with Weekly Paclitaxel for Advanced Breast Cancer: A Phase I Dose-Finding Trial

C. Rochlitz, S. Aebi, P. Brauchli, 2004, Oncology.

Progress on BIG 1-02/IBCSG 27-02/NSABP B-37, a Prospective Randomized Trial Evaluating Chemotherapy after Local Therapy for Isolated Locoregional Recurrences of Breast Cancer

N. Wolmark, E. Mamounas, A. Robidoux, 2008, Annals of Surgical Oncology.

A phase II/pharmacokinetic trial of high-dose progesterone in combination with paclitaxel

S. Aebi, T. Schnider, S. Howell, 1999, Cancer Chemotherapy and Pharmacology.

Differential induction of c-Jun NH2-terminal kinase and c-Abl kinase in DNA mismatch repair-proficient and -deficient cells exposed to cisplatin.

S. Aebi, J. Wang, B. Cenni, 1997, Cancer research.

Hypermethylation of the DPYD promoter region is not a major predictor of severe toxicity in 5-fluorouracil based chemotherapy

U. Amstutz, S. Aebi, C. Largiadèr, 2008, Journal of experimental & clinical cancer research : CR.

Recommendations from the society for diagnosis and therapy of haematological and oncological diseases Breast Cancer in Women

R. Greil, N. Harbeck, M. Hallek, 2018 .

Recommendations from the society for diagnosis and therapy of haematological and oncological diseases Guideline Breast Cancer in Women

R. Greil, C. Bokemeyer, N. Harbeck, 2016 .

The role of DNA mismatch repair in platinum drug resistance.

S. Aebi, B. Cenni, D. Fink, 1996, Cancer research.

Bcl‐xl antisense oligonucleotides induce apoptosis and increase sensitivity of pancreatic cancer cells to gemcitabine

H. Friess, J. Kleeff, M. Büchler, 2001, International journal of cancer.

Quality of life and quality-adjusted survival (Q-TWiST) in patients receiving dose-intensive or standard dose chemotherapy for high-risk primary breast cancer

J. Forbes, R. Gelber, A. Goldhirsch, 2007, British Journal of Cancer.

Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial.

P. Neven, R. Gelber, A. Goldhirsch, 2018, The Lancet. Oncology.

A patient with lung adenocarcinoma and RET fusion treated with vandetanib.

S. Aebi, J. Diebold, K. Strobel, 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Anastrozole (‘Arimidex’) versus tamoxifen as first-line therapy in postmenopausal women with advanced breast cancer: Results of the double-blind cross-over SAKK trial 21/95 - a sub-study of the TARGET (Tamoxifen or ‘Arimidex’ Randomized Group Efficacy and Tolerability) trial

A. Goldhirsch, B. Thürlimann, C. Rochlitz, 2004, Breast Cancer Research and Treatment.

Abstract S6-05: Characterization of male breast cancer: First results of the EORTC10085/TBCRC/BIG/NABCG International Male BC Program

E. Winer, O. Bogler, C. Hudis, 2015 .

A cost-effectiveness analysis of nivolumab versus docetaxel for advanced non-squamous non-small cell lung cancer including PD-L1 testing

S. Aebi, J. Diebold, M. Schwenkglenks, 2016 .

Evaluating the role of ENOSF1 and TYMS variants as predictors in fluoropyrimidine-related toxicities: an IPD meta-analysis.

U. Amstutz, J. Schellens, S. Aebi, 2019, Pharmacological research.

In vitro and in vivo resistance to cisplatin in cells that have lost DNA mismatch repair.

C. Macleod, S. Aebi, M. Haas, 1997, Cancer research.

Poor Prognosis After Second Locoregional Recurrences in the CALOR Trial

R. Gelber, C. Geyer, N. Wolmark, 2017, Annals of Surgical Oncology.

Prognosis of dermal lymphatic invasion with or without clinical signs of inflammatory breast cancer

S. Aebi, H. Altermatt, G. Berclaz, 2004, International journal of cancer.

The effect of real-time electronic monitoring of patient-reported symptoms and clinical syndromes in outpatient workflow of medical oncologists: E-MOSAIC, a multicenter cluster-randomized phase III study

S. Kaasa, F. Strasser, S. Aebi, 2016 .

Do all patients with advanced HER2 positive breast cancer need upfront-chemo when receiving trastuzumab? Randomized phase III trial SAKK 22/99

A. Goldhirsch, J. Bernhard, B. Thürlimann, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Trastuzumab Treatment beyond Progression in Advanced Breast Cancer: Patterns of Care in Six Swiss Breast Cancer Centers

B. Thürlimann, U. Güth, C. Rochlitz, 2011, Oncology.

Brain metastases in gastro-oesophageal adenocarcinoma: insights into the role of the human epidermal growth factor receptor 2 (HER2)

H. Grabsch, H. Moch, S. Hofer, 2015, British Journal of Cancer.

Brain metastases in gastro-oesophageal adenocarcinoma: insights into the role of the human epidermal growth factor receptor 2 (HER2)

H. Grabsch, H. Moch, S. Hofer, 2015, British Journal of Cancer.

Continuous vs intermittent extended adjuvant letrozole for breast cancer: Final results of randomized phase 3 SOLE (Study of Letrozole Extension) and SOLE Estrogen Substudy.

P. Neven, S. Loi, S. Loibl, 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

Quality of life under extended continuous versus intermittent adjuvant letrozole in lymph node-positive, early breast cancer patients: the SOLE randomised phase 3 trial

P. Neven, R. Gelber, H. Gómez, 2019, British Journal of Cancer.

Clinical Implementation of DPYD Pharmacogenetic Testing to Prevent Early-Onset Fluoropyrimidine-Related Toxicity in Cancer Patients in Switzerland

U. Amstutz, S. Aebi, C. Largiadèr, 2022, Frontiers in Pharmacology.

Isolation of the ATP-binding human homolog of the arsA component of the bacterial arsenite transporter.

S. Aebi, S. Howell, P. Naredi, 1996, Genomics.

The Notch pathway in ovarian carcinomas and adenomas

M. Fey, S. Aebi, O. Hopfer, 2005, British Journal of Cancer.

Long-term follow-up of concurrent radiotherapy and chemotherapy for locally advanced cervical cancer: 12-Year survival after radiochemotherapy.

E. Dreher, S. Aebi, G. Berclaz, 2002, International journal of oncology.

Nivolumab for recurrent cutaneous squamous cell carcinoma: three cases

S. Hofer, S. Aebi, J. Diebold, 2018, European Journal of Dermatology.

Principles of systemic therapy

M. Fey, S. Aebi, 2017 .

Fluoropyrimidine chemotherapy: recommendations for DPYD genotyping and therapeutic drug monitoring of the Swiss Group of Pharmacogenomics and Personalised Therapy.

U. Amstutz, S. Aebi, M. Montemurro, 2020, Swiss medical weekly.

Combination Chemotherapy with High-dose Methotrexate and Cytarabine with or without Brain Irradiation for Primary Central Nervous System Lymphomas

S. Aebi, A. Calderoni, 2002, Journal of Neuro-Oncology.

Loss of DNA mismatch repair: effects on the rate of mutation to drug resistance.

S. Aebi, G. Los, D. Fink, 1997, Journal of the National Cancer Institute.

Determination of 5-fluorouracil and 5-fluoro-2'-deoxyuridine-5'-monophosphate in pancreatic cancer cell line and other biological materials using capillary electrophoresis.

H. Friess, S. Aebi, W. Thormann, 2001, Journal of chromatography. A.

Long-term responders to trastuzumab monotherapy in first-line HER-2+ advanced breast cancer: characteristics and survival data

A. Goldhirsch, B. Thürlimann, K. Zaman, 2019, BMC Cancer.

Optimal sequence of tamoxifen and aromatase inhibitors to prevent bone loss.

K. Zaman, S. Aebi, B. Thuerlimann, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Molecular risk assessment of BIG 1-98 participants by expression profiling using RNA from archival tissue

Rolf Jaggi, Mauro Delorenzi, Vlad Popovici, 2010, BMC Cancer.

Bmc Medical Genomics Expression Profiling with Rna from Formalin-fixed, Paraffin-embedded Material

Rolf Jaggi, Mauro Delorenzi, Vlad Popovici, 2022 .

A high-resolution allelotype of B-cell chronic lymphocytic leukemia (B-CLL).

Rolf Jaggi, Jörg Hager, Andreas Tobler, 2002, Blood.

Chemotherapy Prolongs Survival for Isolated Local or Regional Recurrence of Breast Cancer: The CALOR Trial

S. Aebi, T. Rizzo, 2013 .

Abstract S3-2: Chemotherapy prolongs survival for isolated local or regional recurrence of breast cancer: The CALOR trial (Chemotherapy as Adjuvant for Locally Recurrent breast cancer; IBCSG 27-02, NSABP B-37, BIG 1-02)

R. Gelber, N. Wolmark, J. Nortier, 2012 .

Loss of DNA mismatch repair facilitates reactivation of a reporter plasmid damaged by cisplatin

B. Teicher, G. Bubley, S. Aebi, 1999, British Journal of Cancer.

A patient with BRAF V600E lung adenocarcinoma responding to vemurafenib.

S. Aebi, J. Diebold, K. Strobel, 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

all-trans retinoic acid enhances cisplatin-induced apoptosis in human ovarian adenocarcinoma and in squamous head and neck cancer cells.

S. Aebi, B. Cenni, A. Sharma, 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

Medical treatment of nasal squamous papilloma with imiquimod cream

S. Aebi, M. Caversaccio, 2003, The Journal of Laryngology & Otology.

Loss of DNA mismatch repair due to knockout of MSH2 or PMS2 results in resistance to cisplatin and carboplatin.

S. Aebi, D. Fink, S. Howell, 1997, International journal of oncology.

Eribulin as first-line treatment in older patients with advanced breast cancer: A multicenter phase II trial [SAKK 25/14].

U. Hasler-Strub, C. Rochlitz, A. Mueller, 2022, Journal of geriatric oncology.

Capecitabine and vinorelbine in elderly patients (> or =65 years) with metastatic breast cancer: a phase I trial (SAKK 25/99).

A. Goldhirsch, B. Thürlimann, M. Castiglione‐Gertsch, 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

Analgesic action of i.v. morphine-6-glucuronide in healthy volunteers.

S. Aebi, C. Wilder-Smith, T. Buetler, 2000, British journal of anaesthesia.

High-dose chemotherapy for ovarian cancer: are we ready to go?

M. Castiglione‐Gertsch, S. Aebi, 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

Reply to 'Staging for distant metastases in operable breast cancer: a suggested expansion of the ESMO guideline recommendation for staging imaging of node-negative, hormonal receptor-negative disease' by U. Gueth et al.

F. Cardoso, S. Aebi, T. Davidson, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Trastuzumab (T) treatment beyond progression in metastatic breast cancer (MBC): Patterns of care in Swiss clinical practice.

B. Thürlimann, U. Güth, C. Rochlitz, 2010 .

Response to Pembrolizumab in a Patient with Relapsing Thymoma.

R. Winterhalder, S. Aebi, J. Diebold, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

S32 Special Issues Related to Adjuvant Therapy in Very Young Women

S. Aebi, 2005 .

Retinoid receptors in ovarian cancer: expression and prognosis.

S. Aebi, A. Kappeler, M. Körner, 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

Angiosarcoma of the scalp responding to nivolumab: a case report

S. Hofer, S. Aebi, D. Zimmermann, 2018, The British journal of dermatology.

Clinical importance of risk variants in the dihydropyrimidine dehydrogenase gene for the prediction of early‐onset fluoropyrimidine toxicity

U. Amstutz, S. Aebi, M. Joerger, 2014, International journal of cancer.

Novel Genetic Variants in Carboxylesterase 1 Predict Severe Early‐Onset Capecitabine‐Related Toxicity

U. Amstutz, S. Aebi, M. Joerger, 2017, Clinical pharmacology and therapeutics.

The role of DNA mismatch repair in drug resistance.

S. Aebi, D. Fink, S. Howell, 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

The effect of different chemotherapeutic agents on the enrichment of DNA mismatch repair-deficient tumour cells.

S. Aebi, M. Haas, D. Fink, 1998, British Journal of Cancer.

Loss of DNA mismatch repair in acquired resistance to cisplatin.

C. Boland, S. Aebi, R. Fishel, 1996, Cancer research.

Differential expression of p73 splice variants and protein in benign and malignant ovarian tumours

M. Tschan, M. Fey, S. Aebi, 2000, International journal of cancer.

First international consensus guidelines for breast cancer in young women (BCY1).

F. Cardoso, S. Loibl, N. Harbeck, 2014, Breast.

Advances in Brief in Vitro and in Vivo Resistance to Cisplatin in Cells That Have Lost DNA

S. Aebi, D. Fink, P. S. Norris, 2006 .

Dihydropyrimidine dehydrogenase gene variation and severe 5-fluorouracil toxicity: a haplotype assessment.

U. Amstutz, S. Aebi, C. Largiadèr, 2009, Pharmacogenomics.

PRO_10 – A New Tissue-Based Prognostic Multigene Marker in Patients with Early Estrogen Receptor-Positive Breast Cancer

A. Moor, S. Aebi, R. Jaggi, 2011, Pathobiology.

Agents Potentially by Breaching a Damage-Induced Checkpoint Arrest MET Inhibition Results in DNA Breaks and Synergistically Sensitizes Tumor Cells to DNA-Damaging

Yitzhak, S. Aebi, D. Aebersold, 2010 .

Evaluation of multiple transcriptomic gene risk signatures in male breast cancer

E. Winer, O. Bogler, I. Hedenfalk, 2021, NPJ breast cancer.

Chemotherapy for isolated locoregional recurrence of breast cancer (CALOR): a randomised trial.

R. Gelber, C. Geyer, N. Wolmark, 2014, The Lancet. Oncology.

Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph node-positive breast cancer: International Breast Cancer Study Group Trial 13-93.

R. Gelber, A. Goldhirsch, A. Coates, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Multicycle dose-intensive chemotherapy for women with high-risk primary breast cancer: results of International Breast Cancer Study Group Trial 15-95.

R. Gelber, A. Goldhirsch, A. Coates, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Assessment of differences in patient populations selected for excluded from participation in clinical phase III acute myelogenous leukemia trials.

M. Fey, S. Aebi, A. Tobler, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Intensive chemotherapy with whole blood stem-cell support and concurrent chest radiotherapy in small cell lung cancer: a phase I/II trial.

S. Aebi, D. Betticher, A. Calderoni, 2002, Lung cancer.

Ovarian cancer. an institutional review of patterns of care, health insurance and prognosis.

E. Dreher, W. Hänggi, M. Fey, 2000, European journal of cancer.

Is chemotherapy alone adequate for young women with oestrogen-receptor-positive breast cancer?

R. Gelber, A. Goldhirsch, A. Coates, 2000, The Lancet.

Intravascular large B‑cell lymphoma

S. Hofer, S. Aebi, E. Rushing, 2016, memo - Magazine of European Medical Oncology.

Expression of the DNA mismatch repair proteins hMLH1 and hPMS2 in normal human tissues.

S. Aebi, D. Fink, R. Christen, 1997, British Journal of Cancer.

CA15-3 and alkaline phosphatase as predictors for breast cancer recurrence: a combined analysis of seven International Breast Cancer Study Group trials.

A. Goldhirsch, J. Collins, B. Thürlimann, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

The impact of ABCC11 polymorphisms on the risk of early-onset fluoropyrimidine toxicity

U. Amstutz, S. Aebi, M. Joerger, 2016, The Pharmacogenomics Journal.

Differential efficacy of three cycles of CMF followed by tamoxifen in patients with ER-positive and ER-negative tumors: long-term follow up on IBCSG Trial IX.

R. Gelber, B. Gusterson, A. Goldhirsch, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

Evaluation of multiple transcriptomic gene risk signatures in male breast cancer

O. Bogler, I. Hedenfalk, P. Porter, 2021, npj Breast Cancer.

Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

M. Castiglione, S. Aebi, T. Davidson, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

Adjuvant chemotherapy followed by goserelin compared with either modality alone: the impact on amenorrhea, hot flashes, and quality of life in premenopausal patients--the International Breast Cancer Study Group Trial VIII.

J. Forbes, R. Gelber, A. Goldhirsch, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Partial response to dabrafenib and trametinib in relapsed BRAF V600E-Mutated multiple myeloma and possible mechanisms of resistance

S. Aebi, T. Zander, A. Zander, 2022, BMJ Case Reports.

Efficacy of Chemotherapy for ER-Negative and ER-Positive Isolated Locoregional Recurrence of Breast Cancer: Final Analysis of the CALOR Trial.

R. Gelber, C. Geyer, N. Wolmark, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Controversies of adjuvant endocrine treatment for breast cancer and recommendations of the 2007 St Gallen conference.

M. Castiglione‐Gertsch, S. Aebi, M. Rabaglio, 2007, The Lancet. Oncology.

Adjuvant treatment recommendations for patients with ER-positive/HER2-negative early breast cancer by Swiss tumor boards using the 21-gene recurrence score (SAKK 26/10)

R. Winterhalder, C. Rochlitz, T. Ruhstaller, 2017, BMC Cancer.

Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

F. Cardoso, S. Aebi, T. Davidson, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

Infiltrating lobular carcinoma of the breast: systemic treatment.

S. Aebi, S. Farese, 2008, Breast disease.

Successful AZD9291 Therapy Based on Circulating T790M.

S. Aebi, L. Heukamp, O. Gautschi, 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Breast cancer during pregnancy: medical therapy and prognosis.

S. Loibl, S. Aebi, S. Loibl, 2008, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

Resistance to cytotoxic drugs in DNA mismatch repair-deficient cells.

J. L. Fink, S. Aebi, D. Fink, 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

Treatment of Premenopausal Women with Early Breast Cancer

S. Aebi, O. Pagani, 2012, Drugs.

Chemotherapy--overview and future perspectives.

S. Aebi, 2006, Breast.

MET Inhibition Results in DNA Breaks and Synergistically Sensitizes Tumor Cells to DNA-Damaging Agents Potentially by Breaching a Damage-Induced Checkpoint Arrest.

S. Aebi, D. Aebersold, M. Medo, 2010, Genes & cancer.

Overexpression of the p 73 gene is a novel finding in high-risk B-cell chronic lymphocytic leukemia

M. Tschan, M. Fey, S. Aebi, 2005 .

Overexpression of the p73 gene is a novel finding in high-risk B-cell chronic lymphocytic leukemia.

M. Tschan, M. Fey, S. Aebi, 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

Activity of raltitrexed and gemcitabine in advanced pancreatic cancer.

H. Friess, M. Büchler, S. Aebi, 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

[Male Breast Cancer: What is Different?].

S. Aebi, Susanne Bucher, P. Niederberger, 2016, Praxis.

Adherence to ESMO clinical recommendations for prophylaxis of chemotherapy-induced nausea and vomiting

M. Fey, S. Aebi, O. Gautschi, 2010, Supportive Care in Cancer.

Assessment of the management of carcinomatous meningitis from breast cancer globally: a study by the Breast International Group Brain Metastasis Task Force

H. Tesch, S. Aebi, D. Fumagalli, 2022, ESMO open.

Locoregional Recurrence After Mastectomy

S. Aebi, I. Wapnir, J. Tsai, 2018 .

Efficacy and Tolerability of Capecitabine with Weekly Paclitaxel for Patients with Metastatic Breast Cancer: A Phase II Report of the SAKK

C. Rochlitz, S. Aebi, P. Ballabeni, 2007, Oncology.

Population-level effect of molecular testing and targeted therapy in patients with advanced pulmonary adenocarcinoma: a prospective cohort study

D. Pfeiffer, S. Aebi, J. Diebold, 2018, Virchows Archiv.

In vitro antineoplastic activity of a novel lanthionine-containing peptide.

S. Aebi, M. Goodman, P. Law, 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

Bone mineral density in breast cancer patients treated with adjuvant letrozole, tamoxifen, or sequences of letrozole and tamoxifen in the BIG 1-98 study (SAKK 21/07).

A. Giobbie-Hurder, B. Thürlimann, K. Zaman, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Long-term responders to trastuzumab monotherapy in first-line HER-2+ advanced breast cancer: characteristics and survival data

A. Goldhirsch, B. Thürlimann, K. Zaman, 2019, BMC Cancer.

Adjuvant Chemotherapy for Locoregional Recurrent Breast Cancer

Joseph P. Costantino, Stewart J. Anderson, Norman Wolmark, 2011 .

A randomized clinical trial of adjuvant chemotherapy for radically resected locoregional relapse of breast cancer: IBCSG 27-02, BIG 1-02, and NSABP B-37.

R. Gelber, M. Piccart, J. Costantino, 2008, Clinical breast cancer.

Complement Activation and Rituximab Distribution in CNS NHL—Letter

S. Hofer, S. Aebi, M. Schmitt, 2015, Clinical Cancer Research.

Adjuvant endocrine therapy for the very young patients.

M. Castiglione‐Gertsch, S. Aebi, 2003, Breast.

The effect of endocrine responsiveness on high-risk breast cancer treated with dose-intensive chemotherapy: results of International Breast Cancer Study Group Trial 15-95 after prolonged follow-up.

A. Goldhirsch, G. Viale, K. Price, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

Anemia during adjuvant non-taxane chemotherapy for early breast cancer: Incidence and risk factors from two trials of the International Breast Cancer Study Group

A. Goldhirsch, A. Coates, D. Crivellari, 2007, Supportive Care in Cancer.

Quality of life under extended continuous versus intermittent adjuvant letrozole in lymph node-positive, early breast cancer patients: the SOLE randomised phase 3 trial

P. Neven, R. Gelber, H. Gómez, 2019, British Journal of Cancer.

Bone mineral density and circulating biomarkers in the BIG 1-98 trial comparing adjuvant letrozole, tamoxifen and their sequences

R. Gelber, A. Goldhirsch, A. Coates, 2014, Breast Cancer Research and Treatment.

Locally advanced breast cancer

S. Aebi, P. Karlsson, I. Wapnir, 2021, Breast.

Letter comments on EJC published article: Phase I feasibility study for intrathecal administration of trastuzumab in patients with HER2-positive breast carcinomatous meningitis.

S. Hofer, S. Aebi, 2018, European journal of cancer.

Routine adjuvant use of bisphosphonates in breast cancer arguments in favour and against.

S. Aebi, I. Diel, 2010, Critical reviews in oncology/hematology.

Dihydropyrimidinase and β-ureidopropionase gene variation and severe fluoropyrimidine-related toxicity.

U. Amstutz, S. Aebi, M. Joerger, 2015, Pharmacogenomics (London).

S. Kaasa, D. Blum, F. Strasser, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Endocrine therapy plus zoledronic acid in premenopausal breast cancer.

R. Gelber, S. Aebi, 2009, The New England journal of medicine.

Special issues related to the adjuvant therapy in very young women.

S. Aebi, 2005, Breast.

Mutation Profiling of Lung Cancers with Long-Term Response to Gefitinib Therapy

C. Mamot, S. Aebi, R. Büttner, 2015, Oncology Research and Treatment.

Chemotherapy (CT) for isolated locoregional recurrence (ILRR) of breast cancer in ER-positive (ER+) and ER-negative (ER-) cohorts: Final analysis of the CALOR trial.

R. Gelber, N. Wolmark, J. Nortier, 2017 .

Alternate-day dosing of pomalidomide in relapsed/ refractory multiple myeloma: a multicenter, single-arm phase 2 trial

S. Aebi, T. Pabst, S. Schär, 2023, Leukemia.

Spotlight on pomalidomide: could less be more?

S. Aebi, T. Pabst, C. Renner, 2017, Leukemia.

Characterization of molecular scores and gene expression signatures in primary breast cancer, local recurrences and brain metastases

V. Popovici, S. Aebi, R. Jaggi, 2019, BMC Cancer.

1971 A correlative study of Ki67 and two multigene RNA expression signatures in operable ER-positive postmenopausal breast cancer (SAKK 26/10)

R. Winterhalder, S. Aebi, R. Jaggi, 2015 .

Invasive breast cancer and ductal carcinoma in situ in young women

S. Aebi, G. Gruber, 2009 .

The voice of a special patient.

S. Aebi, 2009, Cancer treatment and research.

Activity of Gemcitabine and Continuous Infusion Fluorouracil in Advanced Pancreatic Cancer

H. Friess, M. Büchler, C. Maurer, 2000, Oncology.

Brain metastases in gastro-oesophageal adenocarcinoma: insights into the role of the human epidermal growth factor receptor 2 (HER2)

H. Grabsch, H. Moch, S. Hofer, 2015, British Journal of Cancer.

Brain metastases in gastro-oesophageal adenocarcinoma: insights into the role of the human epidermal growth factor receptor 2 (HER2)

H. Grabsch, H. Moch, S. Hofer, 2015, British Journal of Cancer.

Endometrial cancer: a frequent orphan disease.

S. Aebi, 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

Adjuvant treatment recommendations for patients with ER-positive/HER2-negative early breast cancer by Swiss tumor boards using the 21-gene recurrence score (SAKK 26/10)

R. Winterhalder, C. Rochlitz, A. Mueller, 2017, BMC Cancer.

Increase in tumor GADD153 mRNA level following treatment correlates with response to paclitaxel

S. Aebi, S. Howell, G. Los, 2000, Cancer Chemotherapy and Pharmacology.

Synergy between cisplatin and an inhibitor of S-adenosylmethionine dependent transmethylation in human ovarian adenocarcinoma cells.

S. Aebi, B. Cenni, P. Naredi, 1997, International journal of oncology.

[Sentinel lymphadenectomy: an alternative to axillary lymphadenectomy in breast carcinoma].

E. Dreher, W. Hänggi, M. Fey, 1998, Schweizerische medizinische Wochenschrift.

Rapid response to trastuzumab emtansine in a patient with HER2-driven lung cancer.

S. Aebi, J. Diebold, K. Strobel, 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Characterization of molecular scores and gene expression signatures in primary breast cancer, local recurrences and brain metastases

V. Popovici, S. Aebi, R. Jaggi, 2019, BMC Cancer.

Molecular characterization of breast cancer cell pools with normal or reduced ability to respond to progesterone: a study based on RNA-seq

S. Aebi, R. Jaggi, I. Keller, 2023, Journal of Genetic Engineering and Biotechnology.

Expression profiling with RNA from formalin-fixed, paraffin-embedded material

M. Delorenzi, V. Popovici, S. Aebi, 2008 .

INOVATYON/ ENGOT-ov5 study: Randomized phase III international study comparing trabectedin/pegylated liposomal doxorubicin (PLD) followed by platinum at progression vs carboplatin/PLD in patients with recurrent ovarian cancer progressing within 6-12 months after last platinum line

D. Katsaros, L. Cavanna, I. Meinhold-Heerlein, 2023, British Journal of Cancer.

Expression profiling with RNA from formalin-fixed, paraffin-embedded material.

M. Delorenzi, V. Popovici, S. Aebi, 2008, BMC medical genomics.

Bmc Medical Genomics Expression Profiling with Rna from Formalin-fixed, Paraffin-embedded Material

M. Delorenzi, V. Popovici, S. Aebi, 2022 .

Successful AZD9291 Therapy Based on Circulating T790M.

S. Aebi, L. Heukamp, O. Gautschi, 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Locally advanced breast cancer

S. Aebi, P. Karlsson, I. Wapnir, 2021, Breast.

A Cost‐Effectiveness Analysis of Nivolumab versus Docetaxel for Advanced Nonsquamous NSCLC Including PD‐L1 Testing

S. Aebi, J. Diebold, M. Schwenkglenks, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Response to Pembrolizumab in a Patient with Relapsing Thymoma.

R. Winterhalder, S. Aebi, J. Diebold, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

First international consensus guidelines for breast cancer in young women (BCY1).

F. Cardoso, S. Loibl, N. Harbeck, 2014, Breast.